In adults who have T2D and diabetic nephropathy (ie, DKD) with albuminuria >300 mg/day, INVOKANA® is the only SGLT2i proven to slow the progression of DKDand reduce the risk of hospitalization for heart failure1-4
The only T2D therapy approved by the FDA to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults who have T2D and diabetic nephropathy with albuminuria >300 mg/day1
In adults with DKD* and T2D,
Proven safety profile in patients with an eGFR of 30 to <901
eGFR is measured in mL/min/1.73 m 2.
*With albuminuria >300 mg/day.
†End-stage kidney disease was defined as dialysis for ≥30 days, kidney transplantation, or an eGFR <15 mL/min/1.73 m 2 sustained for ≥30 days.
‡There were not enough events to evaluate the risk of renal death (placebo, n=5; INVOKANA®, n=2). INVOKANA® is not indicated to reduce the risk of renal death.
§RRR was calculated using the following formula: 100 x (1–HR).
AEs=adverse events; CV=cardiovascular; DKA=diabetic ketoacidosis; DKD=diabetic kidney disease; GMI=genital mycotic infection; RRR=relative risk reduction; SGLT2i=sodium-glucose co-transporter 2 inhibitor; T2D=type 2 diabetes.
References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Jardiance® [prescribing information]. Ridgefield, CT: Boehringer lngelheim Pharmaceuticals, Inc. 3. Farxiga® [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 4. Steglatro TM [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. 5. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. Supplementary appendix available at: doi:10.1056/NEJMoa1811744. 6. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140(9):739-750.